336 related articles for article (PubMed ID: 26091640)
1. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Pugsley MK; Curtis MJ; Hayes ES
Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
[TBL] [Abstract][Full Text] [Related]
2. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
Lee N; Authier S; Pugsley MK; Curtis MJ
Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
[TBL] [Abstract][Full Text] [Related]
4. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
[TBL] [Abstract][Full Text] [Related]
5. The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model.
Morissette P; Nishida M; Trepakova E; Imredy J; Lagrutta A; Chaves A; Hoagland K; Hoe CM; Zrada MM; Travis JJ; Zingaro GJ; Gerenser P; Friedrichs G; Salata JJ
J Pharmacol Toxicol Methods; 2013; 68(1):137-49. PubMed ID: 23649000
[TBL] [Abstract][Full Text] [Related]
6. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
7. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
[TBL] [Abstract][Full Text] [Related]
8. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
Fermini B; Hancox JC; Abi-Gerges N; Bridgland-Taylor M; Chaudhary KW; Colatsky T; Correll K; Crumb W; Damiano B; Erdemli G; Gintant G; Imredy J; Koerner J; Kramer J; Levesque P; Li Z; Lindqvist A; Obejero-Paz CA; Rampe D; Sawada K; Strauss DG; Vandenberg JI
J Biomol Screen; 2016 Jan; 21(1):1-11. PubMed ID: 26170255
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
Cavero I; Holzgrefe H
Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
[TBL] [Abstract][Full Text] [Related]
10. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
11. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity and Specificity of the In Vitro Guinea Pig Papillary Muscle Action Potential Duration for the Assessment of Drug-Induced Torsades De Pointes Liability in Humans.
Ducroq J
Handb Exp Pharmacol; 2015; 229():205-19. PubMed ID: 26091641
[TBL] [Abstract][Full Text] [Related]
13. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
14. Electrocardiographic biomarkers to confirm drug's electrophysiological effects used for proarrhythmic risk prediction under CiPA.
Vicente J; Hosseini M; Johannesen L; Strauss DG
J Electrocardiol; 2017; 50(6):808-813. PubMed ID: 28928044
[TBL] [Abstract][Full Text] [Related]
15. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
[TBL] [Abstract][Full Text] [Related]
16. Early drug development: assessment of proarrhythmic risk and cardiovascular safety.
Lester RM; Olbertz J
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1611-1618. PubMed ID: 27718759
[TBL] [Abstract][Full Text] [Related]
17. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
18. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
Wallis R; Benson C; Darpo B; Gintant G; Kanda Y; Prasad K; Strauss DG; Valentin JP
J Pharmacol Toxicol Methods; 2018; 93():15-25. PubMed ID: 29958940
[TBL] [Abstract][Full Text] [Related]
19. Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.
Authier S; Pugsley MK; Koerner JE; Fermini B; Redfern WS; Valentin JP; Vargas HM; Leishman DJ; Correll K; Curtis MJ
J Pharmacol Toxicol Methods; 2017 Jul; 86():34-43. PubMed ID: 28223123
[TBL] [Abstract][Full Text] [Related]
20. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models.
Joshi A; Dimino T; Vohra Y; Cui C; Yan GX
J Electrocardiol; 2004; 37 Suppl():7-14. PubMed ID: 15534787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
